Advanced characterization of DNA molecules in rAAV vector preparations by single-stranded virus next-generation sequencing

Molecular Therapy Nucleic Acids

Volumn 4, Issue 10, 2015, Pages e260-

  Lecomte, Emilie ^a,b,c   Tournaire, Benoît ^a,b,c   Cogné, Benjamin ^a,b,c   Dupont, Jean Baptiste ^a,b,c   Lindenbaum, Pierre ^b,c,d   Martin Fontaine, Mélanie ^a,b,c   Broucque, Frédéric ^a,b,c   Robin, Cécile ^a,b,c   Hebben, Matthias ^e   Merten, Otto Wilhelm ^e   Blouin, Véronique ^a,b,c   François, Achille ^a,b,c   Redon, Richard ^b,c,d   Moullier, Philippe ^a,b,c,f   Léger, Adrien ^a,b,c  

^a UNIVERSITÉ DE NANTES   (France)

^b UNIVERSITÉ DE NANTES   (France)

^c NANTES UNIVERSITY HOSPITAL   (France)

^d L INSTITUT DU THORAX   (France)

^e GÉNÉTHON   (France)

^f UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

DNA contaminants; Next generation sequencing; Quality control; RAAV

Indexed keywords

ADENOVIRUS VECTOR; BACTERIOPHAGE DNA; GENOMIC DNA; MITOCHONDRIAL DNA; PLASMID VECTOR;

ADENO ASSOCIATED VIRUS; AFFINITY CHROMATOGRAPHY; ARTICLE; CHROMOSOME 15; CONTROLLED STUDY; DNA CONTAMINATION; DNA DETERMINATION; DNA SEQUENCE; GENETIC VARIABILITY; GENOME; HUMAN; ION EXCHANGE CHROMATOGRAPHY; NEXT GENERATION SEQUENCING; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; QUALITY CONTROL; QUANTITATIVE ANALYSIS; RECOMBINANT ADENO ASSOCIATED VIRUSES; SINGLE-STRANDED DNA VIRUS; TRANSIENT TRANSFECTION; VIRUS RECOMBINANT;

EID: 84959337169     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2015.32     Document Type: Article

References (34)

1. Pierce, EA and Bennett, J (2015). The status of RPE65 gene therapy trials: safety and efficacy. Cold Spring Harb Perspect Med 5: 9.
2. Nathwani, AC, Tuddenham, EG, Rangarajan, S, Rosales, C, McIntosh, J, Linch, DC et al. (2011). Adenovirus-associated virus vector-mediated gene transfer in hemophilia B. N Engl J Med 365: 2357-2365.
3. Gao, K, Li, M, Zhong, L, Su, Q, Li, J, Li, S et al. (2014). Empty virions in AAV8 vector preparations reduce transduction efficiency and may cause total viral particle dose-limiting side-effects. Mol Ther Methods Clin Dev 1: 20139.
4. Allen, JM, Debelak, DJ, Reynolds, TC and Miller, AD (1997). Identification and elimination of replication-competent adeno-associated virus (AAV) that can arise by nonhomologous recombination during AAV vector production. J Virol 71: 6816-6822.
5. Dong, B, Duan, X, Chow, HY, Chen, L, Lu, H, Wu, W et al. (2014). Proteomics analysis of co-purifying cellular proteins associated with rAAV vectors. PLoS One 9: e86453.
6. Allay, JA, Sleep, S, Long, S, Tillman, DM, Clark, R, Carney, G et al. (2011). Good manufacturing practice production of self-complementary serotype 8 adeno-associated viral vector for a hemophilia B clinical trial. Hum Gene Ther 22: 595-604.
7. Ye, GJ, Scotti, MM, Liu, J, Wang, L, Knop, DR and Veres, G (2011). Clearance and characterization of residual HSV DNA in recombinant adeno-associated virus produced by an HSV complementation system. Gene Ther 18: 135-144.
8. Martino, AT, Suzuki, M, Markusic, DM, Zolotukhin, I, Ryals, RC, Moghimi, B et al. (2011). The genome of self-complementary adeno-associated viral vectors increases Toll-like receptor 9-dependent innate immune responses in the liver. Blood 117: 6459-6468.
9. Faust, SM, Bell, P, Cutler, BJ, Ashley, SN, Zhu, Y, Rabinowitz, JE et al. (2013). CpG-depleted adeno-associated virus vectors evade immune detection. J Clin Invest 123: 2994-3001.
10. FDA Vaccines and Related Biological Products Advisory Committee (2012). FDA Briefing Document: Cell Lines Derived from Human Tumors for Vaccine Manufacture. http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/BloodVaccinesandOtherBiologics/VaccinesandRelatedBiologicalProductsAdvisoryCommittee/UCM319573.pdf.
11. Chadeuf, G, Ciron, C, Moullier, P and Salvetti, A (2005). Evidence for encapsidation of prokaryotic sequences during recombinant adeno-associated virus production and their in vivo persistence after vector delivery. Mol Ther 12: 744-753.
12. Wright, JF and Zelenaia, O (2011). Vector characterization methods for quality control testing of recombinant adeno-associated viruses. Methods Mol Biol 737: 247-278.
13. Noordman, Y, Lubelski, J and Bakker, AC (2013). Mutated rep encoding sequences for use in AAV production. http://www.google.com/patents/US20130023034.
14. Nony, P, Chadeuf, G, Tessier, J, Moullier, P and Salvetti, A (2003). Evidence for packaging of rep-cap sequences into adeno-associated virus (AAV) type 2 capsids in the absence of inverted terminal repeats: a model for generation of rep-positive AAV particles. J Virol 77: 776-781.
15. Hauck, B, Murphy, SL, Smith, PH, Qu, G, Liu, X, Zelenaia, O et al. (2009). Undetectable transcription of cap in a clinical AAV vector: implications for preformed capsid in immune responses. Mol Ther 17: 144-152.
16. Lu, H, Qu, G, Yang, X, Xu, R and Xiao, W (2011). Systemic elimination of de novo capsid protein synthesis from replication-competent AAV contamination in the liver. Hum Gene Ther 22: 625-632.
17. Kapranov, P, Chen, L, Dederich, D, Dong, B, He, J, Steinmann, KE et al. (2012). Native molecular state of adeno-associated viral vectors revealed by single-molecule sequencing. Hum Gene Ther 23: 46-55.
18. Wang, Y, Ling, C, Song, L, Wang, L, Aslanidi, GV, Tan, M et al. (2012). Limitations of encapsidation of recombinant self-complementary adeno-associated viral genomes in different serotype capsids and their quantitation. Hum Gene Ther Methods 23: 225-233.
19. Bryant, LM, Christopher, DM, Giles, AR, Hinderer, C, Rodriguez, JL, Smith, JB et al. (2013). Lessons learned from the clinical development and market authorization of Glybera. Hum Gene Ther Clin Dev 24: 55-64.
20. Ayuso, E, Blouin, V, Lock, M, McGorray, S, Leon, X, Alvira, MR et al. (2014). Manufacturing and characterization of a recombinant adeno-associated virus type 8 reference standard material. Hum Gene Ther 25: 977-987.
21. Louis, N, Evelegh, C and Graham, FL (1997). Cloning and sequencing of the cellular-viral junctions from the human adenovirus type 5 transformed 293 cell line. Virology 233: 423-429.
22. Nicholls, TJ and Minczuk, M (2014). In D-loop: 40 years of mitochondrial 7S DNA. Exp Gerontol 56: 175-181.
23. Aiken, JM, Williamson, JL, Borchardt, LM and Marsh, RF (1990). Presence of mitochondrial D-loop DNA in scrapie-infected brain preparations enriched for the prion protein. J Virol 64: 3265-3268.
24. European Medicines Agency (2012). Glybera: EPAR - Public assessment report. http://www.ema.europa.eu/docs/en-GB/document-library/EPAR-Public-assessment-report/human/002145/WC500135476.pdf.
25. Wilson, JM (2015). A call to arms for improved vector analytics! Hum Gene Ther Methods 26: 1-2.
26. Gavin, DK (2015). FDA statement regarding the use of adeno-associated virus reference standard materials. Hum Gene Ther Methods 26: 3.
27. Strong, MJ, Xu, G, Morici, L, Splinter Bon-Durant, S, Baddoo, M, Lin, Z et al. (2014). Microbial contamination in next generation sequencing: implications for sequence-based analysis of clinical samples. PLoS Pathog 10: e1004437.
28. Laurence, M, Hatzis, C and Brash, DE (2014). Common contaminants in next-generation sequencing that hinder discovery of low-abundance microbes. PLoS One 9: e97876.
29. Aird, D, Ross, MG, Chen, WS, Danielsson, M, Fennell, T, Russ, C et al. (2011). Analyzing and minimizing PCR amplification bias in Illumina sequencing libraries. Genome Biol 12: R18.
30. Cogné, B, Snyder, R, Lindenbaum, P, Dupont, JB, Redon, R, Moullier, P et al. (2014). NGS library preparation may generate artifactual integration sites of AAV vectors. Nat Med 20: 577-578.
31. Thorne, BA, Takeya, RK and Peluso, RW (2009). Manufacturing recombinant adeno-associated viral vectors from producer cell clones. Hum Gene Ther 20: 707-714.
32. Smith, RH, Levy, JR and Kotin, RM (2009). A simplified baculovirus-AAV expression vector system coupled with one-step affinity purification yields high-titer rAAV stocks from insect cells. Mol Ther 17: 1888-1896.
33. Ayuso, E, Mingozzi, F, Montane, J, Leon, X, Anguela, XM, Haurigot, V et al. (2010). High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther 17: 503-510.
34. Kozarewa, I and Turner, DJ (2011). 96-plex molecular barcoding for the Illumina Genome Analyzer. Methods Mol Biol 733: 279-298.